Clinical trial · Observational
Clinical Evaluation for Sarcoma Originated From Bone
NCT03358992CI-TRIAL-00035786CESOFBunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating primary sarcoma originated from bone treated with chemotherapy or targeted therapy, which did not have the definition of measurement methods either. This study evaluates whether clinical imaging findings of sarcoma after preoperative chemotherapy correlate with tumor responses by pathological evaluation by Huvos classifications and develops reliable, quantitative, clinical response criteria.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Histological Response | — | UNRESOLVED | — |
| Sensitivity | — | UNRESOLVED | — |
| Specificity | — | UNRESOLVED | — |
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Sensitivity
- timeFrame
- 12 months
- description
- Sensitivity is defined as the true right clinical evaluated number/ the pathological evaluated number by different classification system.
- measure
- Specificity
- timeFrame
- 12 months
- description
- Specificity is defined as the true wrong clincial evuluated number /the pathological evaluated number by different classification system.
- measure
- Pathological response rate
- timeFrame
- 12 months
- description
- tumor necrosis rate descripted by Huvos
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 1\) histologically confirmed high-grade osteosarcoma; * 2\) initially treated in Musculoskeletal Tumor Center of Peking University People's Hospital, Xijing Hospital or The Second Hospital affiliated to Zhejiang Hospital; * 3\) imaging evaluation should be available; * 4\) completed neo-adjuvant chemotherapy and at least 8 cycles of adjuvant chemotherapy; * 5\) expected to live longer than 3 months with Eastern Cooperative Oncology Group performance status of 0 or 1; * 6\) acceptable hematologic, hepatic, and renal function. Exclusion Criteria: * 1\) Patients who could not complete neo-adjuvant chemotherapy or at least 4-month adjuvant chemotherapy; * 2\) lost to follow-up.
References
Publications (0)
Data not yet available
No reference posted for this study.